BioSpace News Archive

Fresenius Kabi Signs Exclusive U.S. Distribution Agreement with Corvida Medical for the HALO ® Closed System Drug-Transfer Device Enhances Fresenius Kabi’s extensive offerings in oncology care

PharmaCyte Biotech, Inc. (OTCQB: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today that it has successfully completed the twelve-months product stability testing required by the U.S. Food and Drug Administration (FDA) for its CypCaps™ final clinical trial product.

BIO-CAT Microbials, LLC is pleased to announce receipt of a “Letter of No Objection” from the United States Food and Drug Administration regarding the GRAS (generally regarded as safe) status of its OPTI-BIOME® Bacillus subtilis MB40 microbial ingredient; reference GRN 955 for further details

Bioverge, Inc. (“Bioverge”), an investment platform that funds visionary entrepreneurs who are transforming healthcare and bringing science fiction to life, today announced it has launched an equity crowdfunding platform called Bioverge Portal.

Life Sciences organizations can now turn to the MedPro ComplianceReportingIDTM solution for all their Aggregate Spend reporting needs

3M Health Information Systems has introduced a new technology platform that allows health care providers and payers to prioritize care and allocate resources for high-risk individuals and patient populations.

Heathrow Scientific, LLC celebrates 25 years as a global manufacturer of bench top equipment and lab essentials.

Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today announced the appointment of biotechnology industry research and development veteran, William Kennedy, M.D., as Senior Vice President, Clinical, effective Thursday, April 1.

Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced that ARCALYST ® (rilonacept), a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1 alpha (IL-1α) and interleukin-1 beta (IL-1β) signaling

Psirenity, a wholly owned subsidiary of New Leaf Canada Inc., today announced it has signed a two-year partnership with Jamaica’s Scientific Research Council (SRC) to conduct cooperative studies into the beneficial effects of psilocybin mushrooms.